Insiders · LYEL

LYEL insider transactions

Lyell Immunopharma Inc. (LYEL) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.

Recent Form 3, 4, and 5 filings for LYEL

• 1d
  Large owner Innovative Cellular Therapeutics Holdings Ltd sold $137 worth of shares (10 units at $13.73), decreasing direct ownership by 0.00% to 2,857,490 units (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 17d
  Large owner Innovative Cellular Therapeutics Holdings Ltd disposed of 76,000 shares, decreasing direct ownership by 3% to 2,857,500 units (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 30d
  Large owner Innovative Cellular Therapeutics Holdings Ltd disposed of 66,500 shares, decreasing direct ownership by 2% to 2,933,500 units (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 30d
  New insider Innovative Cellular Therapeutics Holdings Ltd claimed ownership of 3,000,000 shares (SEC Form 3)

  3 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 33d
  President and CEO Seely Lynn sold $7,337 worth of shares (388 units at $18.91), decreasing direct ownership by 0.52% to 73,878 units (SEC Form 4) (tax withholding)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 33d
  Chief Scientific Officer Lee Gary K. sold $2,460 worth of shares (130 units at $18.92), decreasing direct ownership by 0.72% to 17,808 units (SEC Form 4) (withholding obligation)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 33d
  Chief Operating Officer Hill Stephen J. sold $1,684 worth of shares (89 units at $18.92), decreasing direct ownership by 0.49% to 17,894 units (SEC Form 4) (tax liability)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 33d
  VP, Corporate Controller Bulis Veronica Sanchez sold $4,103 worth of shares (217 units at $18.91), decreasing direct ownership by 1% to 15,420 units (SEC Form 4) (for withholding tax)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 36d
  SEC Form 4 filed by Director Rieflin William Jl

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 36d
  SEC Form 4 filed by Director Ramachandra Sumant

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 36d
  SEC Form 4 filed by Director Nabel Elizabeth G

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 36d
  SEC Form 4 filed by Director Klausner Richard

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 36d
  SEC Form 4 filed by Director Friedman Cathy

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 36d
  SEC Form 4 filed by Director Brawley Otis W

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 36d
  SEC Form 4 filed by Director Bachleda Mark

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 124d
  SEC Form 4 filed by Chief Fin. and Bus. Officer Shah Smital

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 124d
  SEC Form 3 filed by new insider Shah Smital

  3 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 131d
  Large owner Arch Venture Partners Ix, Llc bought $12,499,985 worth of shares (488,090 units at $25.61) (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 131d
  Large owner Arch Venture Fund Xiii, L.P. bought $12,499,985 worth of shares (488,090 units at $25.61) (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 156d
  President and CEO Seely Lynn sold $174,372 worth of shares (7,455 units at $23.39), decreasing direct ownership by 9% to 74,266 units (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 156d
  Chief Operating Officer Hill Stephen J. sold $28,910 worth of shares (1,236 units at $23.39), decreasing direct ownership by 6% to 17,795 units (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 156d
  Chief Scientific Officer Lee Gary K. sold $39,085 worth of shares (1,671 units at $23.39), decreasing direct ownership by 9% to 16,938 units (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 157d
  Chief Operating Officer Hill Stephen J. was granted 4,000 shares and sold $2,520 worth of shares (109 units at $23.12), increasing direct ownership by 26% to 19,031 units (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 157d
  Chief Scientific Officer Lee Gary K. was granted 4,000 shares and sold $3,399 worth of shares (147 units at $23.12), increasing direct ownership by 26% to 18,609 units (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 157d
  President and CEO Seely Lynn was granted 20,000 shares and sold $10,127 worth of shares (438 units at $23.12), increasing direct ownership by 31% to 81,721 units (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 157d
  SEC Form 4 filed by General Counsel Meltz Mark A

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 157d
  VP, Corporate Controller Bulis Veronica Sanchez was granted 8,750 shares and sold $5,872 worth of shares (254 units at $23.12), increasing direct ownership by 119% to 15,637 units (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 157d
  SEC Form 4 filed by Chief Medical Officer Shook David

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 193d
  VP, Corporate Controller Bulis Veronica Sanchez sold $74,181 worth of shares (2,072 units at $35.80), decreasing direct ownership by 22% to 7,141 units (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 248d
  President and CEO Seely Lynn sold $6,637 worth of shares (412 units at $16.11), decreasing direct ownership by 0.61% to 67,159 units (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 248d
  VP, Corporate Controller Bulis Veronica Sanchez sold $3,848 worth of shares (239 units at $16.10), decreasing direct ownership by 3% to 9,213 units (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 248d
  Chief Scientific Officer Lee Gary K. sold $2,230 worth of shares (138 units at $16.16), decreasing direct ownership by 0.89% to 15,366 units (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 248d
  Chief Operating Officer Hill Stephen J. sold $1,531 worth of shares (95 units at $16.12), decreasing direct ownership by 0.60% to 15,750 units (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 250d
  New insider Bulis Veronica Sanchez claimed ownership of 9,452 shares (SEC Form 3)

  3 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 262d
  SEC Form 4 filed by Chief Operating Officer Hill Stephen J.

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 262d
  SEC Form 4 filed by Chief Scientific Officer Lee Gary K.

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 262d
  SEC Form 4 filed by President and CEO Seely Lynn

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 330d
  President and CEO Seely Lynn was granted 40,000 shares and sold $76,518 worth of shares (7,257 units at $10.54), increasing direct ownership by 94% to 67,571 units (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 330d
  Chief Operating Officer Hill Stephen J. was granted 8,000 shares and sold $10,586 worth of shares (1,004 units at $10.54), increasing direct ownership by 79% to 15,845 units (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 330d
  Chief Financial Officer Newton Charles W. was granted 8,000 shares and sold $15,320 worth of shares (1,453 units at $10.54), increasing direct ownership by 75% to 15,306 units (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 330d
  Chief Scientific Officer Lee Gary K. was granted 8,000 shares and sold $15,320 worth of shares (1,453 units at $10.54), increasing direct ownership by 73% to 15,504 units (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 339d
  President and CEO Seely Lynn sold $8,313 worth of shares (797 units at $10.43), decreasing direct ownership by 2% to 34,828 units (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 339d
  Chief Operating Officer Hill Stephen J. sold $1,930 worth of shares (185 units at $10.43), decreasing direct ownership by 2% to 8,849 units (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 339d
  Chief Scientific Officer Lee Gary K. sold $2,785 worth of shares (267 units at $10.43), decreasing direct ownership by 3% to 8,957 units (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 339d
  Chief Financial Officer Newton Charles W. sold $2,785 worth of shares (267 units at $10.43), decreasing direct ownership by 3% to 8,759 units (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 354d
  SEC Form 4 filed by Large owner Arch Venture Partners Ix, Llc

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 354d
  New insider Arch Venture Fund Xiii, L.P. claimed ownership of 938,438 shares (SEC Form 3)

  3 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 402d
  SEC Form 4 filed by Director Bachleda Mark

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 402d
  SEC Form 4 filed by General Counsel Meltz Mark A

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 402d
  Chief Medical Officer Shook David was granted 21,900 shares (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 402d
  SEC Form 3 filed by new insider Bachleda Mark

  3 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 402d
  SEC Form 3 filed by new insider Meltz Mark A

  3 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 402d
  SEC Form 3 filed by new insider Shook David

  3 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 425d
  SEC Form 4 filed by Director Klausner Richard

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 425d
  SEC Form 4 filed by Director Rieflin William Jl

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 425d
  SEC Form 4 filed by Director Friedman Cathy

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 425d
  SEC Form 4 filed by Director Brawley Otis W

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 425d
  SEC Form 4 filed by Director Nabel Elizabeth G

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 425d
  SEC Form 4 filed by Director Ramachandra Sumant

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 472d
  Director Brawley Otis W bought $19,958 worth of shares (35,640 units at $0.56) (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)